Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

I
T-035
Identifying Determinants of Vaccine Efficacy: A Mechanistic Modeling Approach

Favorite
M-043
Image Processing with Spatial Modeling of Neural Tissue: A New Approach to Pharmacokinetic Analysis

Favorite
M-055
Immune Correlates of Protection against Respiratory Syncytial Virus Infection and an Application to Model-Informed Vaccine Development for an internal compound: a Model-Based Meta-Analysis

Favorite
W-137
Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis

Favorite
M-060
Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia

Favorite
T-061
Impact of PD-L2 on Relative Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies: Insights From QSP-Based Meta-Analysis

Favorite
T-132
Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials

Favorite
W-092
Incorporating Computational Fluid Dynamic Modeling into Pharmacometrics Models for Applications to Gene Therapy, Anti-Inflammatory Treatments and Transdermal Patch Drug Delivery

Favorite
W-108
Incorporating High Dimensional Gut Microbiome Data into Population Pharmacokinetic Modeling of Mycophenolate Mofetil

Favorite
W-020
In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models

Favorite
W-041
Inferring HIV rebound timing from a noisy biomarker

Favorite
W-105
Informing Early Trial Design in Oncology Through Clinical Trial Simulations from Population Pharmacokinetic-Tumor Growth Inhibition Models

Favorite
T-006
Inhibitory Potential of Cannabidiol on Major CYP450s Enzymes: Insights from Physiological-based Pharmacokinetic Modeling

Favorite
T-027
Integrated Microphysiological System and PBPK Modeling for Prediction of Human Diclofenac Pharmacokinetics

Favorite
T-089
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites

Favorite
M-092
Integrated Quantitative Systems Pharmacology and Pharmacometric Model to Evaluate Effective Buprenorphine Induction Treatment Strategies in the Era of Synthetic Opioids

Favorite
W-017
Integrating mathematical modeling with multiplexed immunofluorescence data to predict drug-induced cell arrest

Favorite
T-096
Integrating Motor Function Scores of Spinal Muscular Atrophy in a Quantitative Systems Pharmacology Model of Neurofilament

Favorite
T-134
Integrating Physiologically Based Pharmacokinetic (PBPK) Modeling and Strain-Specific Exposure-Efficacy Requirements to Refine the Dosage Regimens for Voriconazole in a Pediatric Cancer Population

Favorite
M-016
Integrating Physiologically Based Pharmacokinetic Modeling with Machine Learning for the Rational Design of Nanoparticles to Improve Safety in Biomedical Applications

Favorite
M-082
Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib

Favorite
W-093
Integration of Population Pharmacokinetic Model for Tenofovir Alafenamide by External Evaluation

Favorite
T-030
Integration of Temporal Single-Cell RNA Sequencing Data into Quantitative Systems Pharmacology Model of T Cell Differentiation

Favorite
W-076
Interactive Pharmacometric Simulations and Model Exploration with e-Campsis

Favorite
M-015
Intranasal Diamorphine Population Pharmacokinetics Modeling and Simulation in Pediatric Breakthrough Pain

Favorite
W-048
Itacitinib Population Pharmacokinetics (PopPK) and Exposure-Response for Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy: Results From Phase 2 Study NCT04071366

Favorite